Achieve Life Sciences (ACHV) Accounts Payables (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Accounts Payables of $27000.0 in Q1 2026, down 96.86% on a QoQ basis from $859000.0 in Q4 2025, and down 98.37% year-over-year from $1.7 million in Q1 2025.
Achieve Life Sciences (ACHV) Accounts Payables (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Accounts Payables across 17 years of filings, most recently posting $27000.0 for Q1 2026.
- Quarterly Accounts Payables fell 98.37% year-over-year to $27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27000.0 (down 98.37% YoY) and the FY2025 annual result came in at $859000.0, down 55.95% from the prior year.
- Accounts Payables eased to $27000.0 in Q1 2026, from $859000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $2.0 million in Q4 2024 and troughed at $27000.0 in Q1 2026.
- A 5-year average of $906647.1 and a median of $656000.0 in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2025 — Accounts Payables surged 343.97% — and 2026, when it plunged 98.37%.
- Tracing ACHV's Accounts Payables over 5 years: stood at $1.7 million in 2022, then plunged by 62.77% to $618000.0 in 2023, then jumped by 215.53% to $2.0 million in 2024, then plunged by 55.95% to $859000.0 in 2025, then tumbled by 96.86% to $27000.0 in 2026.
- Business Quant data shows ACHV's Accounts Payables at $27000.0 in Q1 2026, $859000.0 in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 8.64 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 34.55 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | 27,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 859,000.00 |
| Sep 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.66 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 550,000.00 |
| Mar 31, 2024 | 373,000.00 |
| Dec 31, 2023 | 618,000.00 |
| Sep 30, 2023 | 638,000.00 |
| Jun 30, 2023 | 361,000.00 |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.66 Mn |
| Sep 30, 2022 | 412,000.00 |
| Jun 30, 2022 | 656,000.00 |
| Mar 31, 2022 | 418,000.00 |
| Dec 31, 2021 | 841,000.00 |
| Sep 30, 2021 | 815,000.00 |
| Jun 30, 2021 | 575,000.00 |